Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUE NASDAQ:GRCE NASDAQ:HUMA NASDAQ:IMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$31.12+12.0%$27.39$4.97▼$45.50$130.68M2.45388,084 shs72,832 shsGRCEGrace Therapeutics$2.43+0.8%$2.34$1.79▼$5.18$39.76M0.37463,536 shs46,714 shsHUMAHumacyte$0.66-0.4%$0.97$0.55▼$2.84$145.87M2.528.38 million shs2.17 million shsIMDXOncocyte$4.81+2.2%$5.59$2.33▼$8.51$153.18M1.76241,814 shs19,914 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma-2.46%-23.88%+16.32%-94.91%-96.39%GRCEGrace Therapeutics-0.82%-1.23%+8.56%-47.61%-27.84%HUMAHumacyte-3.23%-5.81%-35.96%-7.12%-72.40%IMDXOncocyte-2.28%-2.89%-11.47%+22.66%+470,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$31.12+12.0%$27.39$4.97▼$45.50$130.68M2.45388,084 shs72,832 shsGRCEGrace Therapeutics$2.43+0.8%$2.34$1.79▼$5.18$39.76M0.37463,536 shs46,714 shsHUMAHumacyte$0.66-0.4%$0.97$0.55▼$2.84$145.87M2.528.38 million shs2.17 million shsIMDXOncocyte$4.81+2.2%$5.59$2.33▼$8.51$153.18M1.76241,814 shs19,914 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma-2.46%-23.88%+16.32%-94.91%-96.39%GRCEGrace Therapeutics-0.82%-1.23%+8.56%-47.61%-27.84%HUMAHumacyte-3.23%-5.81%-35.96%-7.12%-72.40%IMDXOncocyte-2.28%-2.89%-11.47%+22.66%+470,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUECue Biopharma 1.00SellN/AN/AGRCEGrace Therapeutics 2.00Hold$6.00147.02% UpsideHUMAHumacyte 2.75Moderate Buy$6.25851.29% UpsideIMDXOncocyte 2.00Hold$12.00149.32% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, IMDX, HUMA, and CUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2026HUMAHumacyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026IMDXOncocyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/17/2026HUMAHumacyte TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1.50 ➝ $1.256/16/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/11/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.006/8/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/1/2026HUMAHumacyte BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$2.005/26/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.005/18/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.004/28/2026HUMAHumacyte D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 7/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUECue Biopharma$27.47M4.76N/AN/A$10.08 per share3.09GRCEGrace TherapeuticsN/AN/AN/AN/A$4.13 per shareN/AHUMAHumacyte$2.04M71.50N/AN/A$0.02 per share32.85IMDXOncocyte$4.05M38.37N/AN/A($1.10) per share-4.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUECue Biopharma-$26.60M-$5.58N/AN/AN/A-59.65%-98.30%-53.69%8/18/2026 (Estimated)GRCEGrace Therapeutics-$7.79M-$0.48N/AN/AN/AN/A-14.45%-13.58%8/11/2026 (Estimated)HUMAHumacyte-$40.83M-$0.57N/AN/AN/A-4,836.06%-2,914.18%-89.45%8/10/2026 (Estimated)IMDXOncocyte-$50.22M-$1.48N/AN/AN/A-2,454.64%N/A-96.96%N/ALatest GRCE, IMDX, HUMA, and CUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q1 2027GRCEGrace Therapeutics-$0.1293N/AN/AN/A$0.40 millionN/A8/10/2026Q2 2026HUMAHumacyte-$0.10N/AN/AN/A$1.12 millionN/A6/18/2026Q4 2026GRCEGrace Therapeutics-$0.24-$0.07+$0.17-$0.06$0.90 millionN/A5/14/2026Q1 2026CUECue Biopharma-$3.30-$1.08+$2.22-$1.08$2.50 million$5.69 million5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 million5/13/2026Q1 2026IMDXOncocyteN/A-$0.28N/A-$0.12N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCUECue BiopharmaN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUECue BiopharmaN/A3.573.57GRCEGrace TherapeuticsN/A8.108.10HUMAHumacyte5.463.933.32IMDXOncocyteN/A2.542.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUECue Biopharma35.04%GRCEGrace Therapeutics6.08%HUMAHumacyte44.71%IMDXOncocyte55.35%Insider OwnershipCompanyInsider OwnershipCUECue Biopharma14.56%GRCEGrace Therapeutics11.10%HUMAHumacyte3.10%IMDXOncocyte2.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUECue Biopharma604.20 million3.59 millionOptionableGRCEGrace TherapeuticsN/A16.27 million14.47 millionN/AHUMAHumacyte150222.02 million215.14 millionOptionableIMDXOncocyte12032.29 million31.58 millionN/AGRCE, IMDX, HUMA, and CUE HeadlinesRecent News About These CompaniesFavorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay PortfolioJuly 16 at 3:22 PM | globenewswire.comIMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research PaperJune 29, 2026 | globenewswire.comiMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research GrantJune 22, 2026 | globenewswire.comFavorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical ChemistryJune 16, 2026 | globenewswire.comIMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of TransplantationJune 11, 2026 | globenewswire.comInsight Molecular Diagnostics Inc. (IMDX) Shareholder/Analyst Call Prepared Remarks TranscriptJune 11, 2026 | seekingalpha.comiMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant CongressJune 9, 2026 | globenewswire.comInsight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comIMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure CommercializationMay 13, 2026 | globenewswire.comiMDx to Release First Quarter 2026 Results on May 13, 2026May 6, 2026 | globenewswire.comInsider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Acquires 38,880 Shares of StockApril 28, 2026 | insidertrades.comBroadwood Partners, L.P. Purchases 40,114 Shares of Oncocyte (NASDAQ:IMDX) StockApril 21, 2026 | insidertrades.comReal-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure AssayApril 14, 2026 | globenewswire.comInsight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comIMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 ResultsMarch 26, 2026 | globenewswire.comiMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare ConferenceMarch 20, 2026 | globenewswire.comSecond Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model ScoreMarch 13, 2026 | globenewswire.comInsight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA SubmissionMarch 3, 2026 | globenewswire.comBroadwood Partners, L.P. Acquires 521,739 Shares of Oncocyte (NASDAQ:IMDX) StockFebruary 13, 2026 | insidertrades.comiMDx Announces $26.0 Million Registered Direct OfferingFebruary 11, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 20263 Stocks Doing the Heavy Lifting in Healthcare’s ReboundBy Jessica Mitacek | June 18, 2026Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AIBy Jeffrey Neal Johnson | July 2, 20263 Picks-and-Shovels Stocks Powering the Humanoid Robotics BuildoutBy Ryan Hasson | July 17, 2026GRCE, IMDX, HUMA, and CUE Company DescriptionsCue Biopharma NASDAQ:CUE$31.12 +3.33 (+11.96%) As of 01:05 PM Eastern This is a fair market value price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Grace Therapeutics NASDAQ:GRCE$2.43 +0.02 (+0.79%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Humacyte NASDAQ:HUMA$0.66 0.00 (-0.39%) As of 01:05 PM Eastern This is a fair market value price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Oncocyte NASDAQ:IMDX$4.81 +0.10 (+2.19%) As of 01:05 PM Eastern This is a fair market value price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout J.B. Hunt Stock Could Reach $340 as Trucking Capacity Shrinks The AI Data Center Boom Is Bigger Than One Stock—These ETFs Spread the Bet Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
